New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
13:29 EDTCYTXCytori Therapeutics CEO transition likely to be seamless, says Maxim
After Cytori announced that Chris Calhoun would retire as CEO effective immediately and be replaced by Dr. Mark Hedrick, Maxim expects the transition to be seamless. The firm explains that it believes that Hedrick, who is currently president of the company, and Calhoun are interchangeable. The firm thinks the company's fundamentals are solid and keeps a Buy rating on the stock.
News For CYTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
09:22 EDTCYTXOn The Fly: Pre-market Movers
Subscribe for More Information
07:05 EDTCYTXCytori Therapeutics begins enrollment in Phase III Adresu trial
Cytori Therapeutics announced that the first patient has been enrolled and treated in the ADRESU trial, a late phase, physician-initiated Japanese clinical trial to study the efficacy and safety of Cytori Cell Therapy in men with urinary incontinence after prostatic surgery for prostate cancer or benign prostatic hypertrophy. ADRESU is a multicenter, 45 patient open label controlled trial of the ECCI-50 cellular therapeutic and is based on promising pilot trial data published in the International Journal of Urology in 2014. Details of the pilot trial can be found on and the MHLW website. The primary endpoint for the ADRESU trial will be the number of patients who experience reduction of urinary leakage volume 52 weeks after treatment. If the endpoint is successfully achieved, the data will be used to seek approval of Cytori Cell Therapy for this indication. The trial costs are substantially supported by Japan's Ministry of Health, Labour and Welfare, with additional support by Cytori. The trial is sponsored by Nagoya University. The ADRESU trial was based on preliminary safety and efficacy data published in 2014 in the International Journal of Urology. Following enrollment and assessment of the results of the trial, Cytori and Nagoya University intend to file for medical device approval for the therapy, which in Japan is typically combined with reimbursement.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use